Extended Data Fig. 4: TCRA2-2 and TCRA24 T cells mediate HLA-restricted killing in vitro of cell lines naturally expressing the CTNNB1S37F mutation.
From: TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors
a, Activation of CTNNB1-S37F TCR-T cells staining negatively for CD8 (considered CD4 T cells) measured by upregulation of CD137 after co-incubation with Mel888A24 or Hutu80A2, or Mel888A24+A2 or Hutu80A2+A24 cells with or without pulsing with the cognate CTNNB1-S37F peptide (100 nM). Data are from the same experiments as shown for CD8+ T cells in Fig. 2e. One independent experiment using n = 2 different T cell donors; bars show mean, and dots represent the average of n = 3 technical replicates. b, Evaluation of the ability of TCRA2-1, TCRA2-2 and TCRA2-3 to persistently kill the Hutu80A2 cell line upon three repeated challenges with tumor cells using IncuCyte live cell imaging. T cells were rechallenged with fresh target cells each 42 h (final timepoint at 42×3 = 126 h). c, Evaluation of TCRA2-2, TCRA24 and TCR1G4 T cell killing of the Hutu80A2 and Mel888A24 cell lines using IncuCyte live cell imaging. Data in b and c represent mean ± s.e.m. of one experiment with n = 3 technical replicates and (b) n = 2 or (c) n = 1 PBMC donors.
